Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-15,133
Closed -$11.5K 1911
2023
Q1
$11.5K Sell
15,133
-1,412
-9% -$1.31K ﹤0.01% 1760
2022
Q4
$15.9K Buy
16,545
+2,893
+21% +$4.09K ﹤0.01% 1817
2022
Q3
$30K Sell
13,652
-260
-2% -$897 ﹤0.01% 1702
2022
Q2
$48K Sell
13,912
-9,039
-39% -$33.8K ﹤0.01% 1705
2022
Q1
$115K Sell
22,951
-3,785
-14% -$19.2K ﹤0.01% 2005
2021
Q4
$167K Buy
26,736
+11,427
+75% +$78K ﹤0.01% 2092
2021
Q3
$122K Sell
15,309
-15,681
-51% -$129K ﹤0.01% 1885
2021
Q2
$232K Buy
30,990
+16,989
+121% +$119K ﹤0.01% 2058
2021
Q1
$85K Buy
14,001
+2,396
+21% +$18.4K ﹤0.01% 2184
2020
Q4
$66K Buy
+11,605
New +$73.8K ﹤0.01% 2027

Other funds holding VXRT

ProShare Advisors's VXRT Position: Q2 2023 in Review

ProShare Advisors sold out of Vaxart (VXRT) in Q2 2023, closing a stake of 15,133 shares — an estimated $11.5K sold.

ProShare Advisors first reported a position in VXRT in Q4 2020 and held it in 10 quarters. The position peaked at $232K in Q2 2021. 111 funds tracked by Wall St. Rank hold VXRT as of Q2 2023.

  • ProShare Advisors reported no remaining Vaxart position as of Q2 2023 after selling out during the quarter.
  • ProShare Advisors sold 15,133 Vaxart shares in Q2 2023, an estimated $11.5K.
  • ProShare Advisors first reported a position in Vaxart in Q4 2020 and held it in 10 quarters.
  • ProShare Advisors's Vaxart position peaked at $232K in Q2 2021.
  • 111 funds tracked by Wall St. Rank held Vaxart as of Q2 2023.

Based on ProShare Advisors's 13F filing for Q2 2023, filed 10 Aug 2023.